The Democratic Republic of Congo is facing the world's fastest-growing Ebola outbreak on record, with at least 930 deaths and 2,344 confirmed cases as of mid-July. The Bundibugyo virus strain has spread across four provinces in just two months, surpassing 1,000 cases within 40 days of response activation. For comparison, the 2018 Ebola outbreak in North Kivu took 235 days to reach the same milestone.

What makes this outbreak particularly alarming is not just its speed, but what it reveals about global health preparedness. Healthcare workers in the affected regions have almost no tools to fight back. There are no approved treatments for Bundibugyo virus disease, and no vaccines to prevent infection or slow transmission. Patients receive only fluids and supportive care, leaving them to fight the virus with their own immune systems.

Why Did This Outbreak Catch the World Unprepared?

The uncomfortable truth, according to Medecins Sans Frontieres (also known as Doctors Without Borders), is that this crisis was entirely predictable. Previous Bundibugyo outbreaks occurred in 2007 and 2012, and both clearly exposed the same gaps that plague today's response: no approved treatment, no reliable rapid diagnostic test, and no vaccine.

But once those earlier outbreaks subsided, so did the world's attention and funding. Calls from health organizations for sustained investment to close these gaps went unanswered because there was no active crisis to justify the expense. This pattern repeats across multiple infectious diseases. Vaccines and treatments for Ebola virus (formerly called Zaire virus) only emerged after the devastating West Africa epidemic from 2014 to 2016, when the disease became a global security concern. By then, 11,325 people had died.

"Disease preparedness does not fail because it does not work. It fails because the world invests in it only during crises and abandons it once the headlines fade," explained Laura Leyser, Secretary General of Medecins Sans Frontieres International.

Laura Leyser, Secretary General, Medecins Sans Frontieres International

What Challenges Are Slowing the Response on the Ground?

Even with response teams mobilized, the outbreak continues to spread faster than containment efforts can manage. Ituri province remains the epicenter, accounting for 89.6% of all confirmed cases and 83.6% of all reported deaths. The case fatality rate stands at 39%, meaning nearly four in ten infected people die from the disease.

Security incidents affecting health facilities have created severe operational obstacles. These challenges include restricted access for response teams, disruption of surveillance and response activities, and an increased risk of undetected transmission. The World Health Organization (WHO) has emphasized that response efforts must be led by local leaders and anchored in communities to overcome these barriers.

A clinical trial launched this month by the WHO offers some hope. The PARTNERS trial aims to identify the first effective treatments for Bundibugyo virus disease, coordinated by institutions including the National Institute for Biomedical Research in the DRC, the Institute of Tropical Medicine in Belgium, the University of Oxford, and the Africa CDC. Medecins Sans Frontieres is participating in this trial. However, it has taken two decades and yet another deadly outbreak to reach this point.

How Can the World Break This Cycle of Reactive Health Crises?

• Sustained Research Investment: Governments and international bodies must commit to long-term funding for vaccine and treatment development for known threats, not just during active outbreaks. This includes supporting clinical trials and diagnostic test development even when disease activity is low.
• Equitable Access Frameworks: The WHO Pandemic Agreement adopted in 2025 includes a component called Pathogen Access and Benefit Sharing, which aims to ensure vaccines, tests, and treatments reach people who need them most, not just those who can pay. Member states must finalize these rules and attach equitable access conditions to research they fund.
• Strengthening Local Health Systems: Building resilient health infrastructure in conflict-affected regions requires acknowledging African physicians, researchers, and frontline healthcare workers for their knowledge and contributions. Strengthening local institutions and research leadership is essential for future outbreak response.

The broader lesson extends beyond Ebola. Drug-resistant infections have long been recognized as a major public health threat, yet the process of developing new antibiotics remains scientifically challenging and commercially unattractive when antimicrobial resistance has not yet become a full-blown crisis in policymakers' minds. Cholera offers another cautionary tale. Outbreaks have surged since 2017, and vaccine supply has not been able to meet global demand. In 2022, faced with a global shortage, the international body managing emergency cholera vaccine supplies had to switch from a standard two-dose regimen to a single dose to stretch limited supplies across more countries.

The current Ebola outbreak in the DRC demonstrates that prevention is far less expensive than crisis response. The 2014-2016 West Africa Ebola epidemic and the COVID-19 pandemic taught the world that containment strategies alone cannot substitute for sustained investment in research, surveillance, and resilient health systems. The real choice before policymakers is not whether to invest in healthcare readiness, but whether to do so before the next crisis happens.